This company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsPMD Device Solutions（8T00）株式概要PMD Device Solutions AB社はデジタル医療機器会社で、アイルランドで呼吸モニタリング・ソリューションを開発・販売している。 詳細8T00 ファンダメンタル分析スノーフレーク・スコア評価3/6将来の成長2/6過去の実績0/6財務の健全性0/6配当金0/6報酬収益は年間50.94%増加すると予測されています 過去 1 年間で収益は24%増加しました同業他社や業界と比較して、良好な取引価格 リスク分析マイナスの株主資本 意味のある時価総額がありません ( €1M )German市場と比較して、過去 3 か月間の株価の変動が非常に大きいキャッシュランウェイが1年未満である +2 さらなるリスクすべてのリスクチェックを見る8T00 Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair Value€Current Price€0.02799.1% 割安 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-59m307m2016201920222025202620282031Revenue SEK 306.5mEarnings SEK 55.7mAdvancedSet Fair ValueView all narrativesPMD Device Solutions AB 競合他社EpigenomicsSymbol: DB:ECXMarket cap: €815.6kSangui Biotech InternationalSymbol: HMSE:SBHMarket cap: €419.8kco.donSymbol: XTRA:CNWMarket cap: €6.5mMedigeneSymbol: XTRA:MDG1Market cap: €1.8m価格と性能株価の高値、安値、推移の概要PMD Device Solutions過去の株価現在の株価SEK 0.02752週高値SEK 5.4852週安値SEK 0.022ベータ01ヶ月の変化-12.90%3ヶ月変化-87.73%1年変化-97.55%3年間の変化n/a5年間の変化n/aIPOからの変化-97.22%最新ニュースNew Risk • Nov 07New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Negative equity (-kr115m). Market cap is less than US$10m (€5.17m market cap, or US$5.55m). Minor Risks Less than 3 years of financial data is available. Revenue is less than US$5m (kr40m revenue, or US$3.7m).お知らせ • Oct 29PMD Device Solutions AB Approves Board ChangesPMD Device Solutions AB at its EGM held on October 29, 2024 approved that the board of directors shall consist of Martin Roos (new election) and Sten Dahlborg (new election). It was further resolved to elect Sten Dahlborg as chairman of the board. Peter Donnelly therefore resigns as member of the board as well as chairman. Martin Roos: Martin Roos is an INSEAD certified board director (IDP) with board and executive experience from telecom, tech and biotech. He currently serves as the chairman for Seamless Distribution Systems and is a board member of Nexam Chemicals and Redsense Medical (listed on NGM Nordic SME, Nasdaq First North and Spotlight respectively). He also serves on the board of startups such as Lignin Industries. Martin has previously served on the board operating committee of WOM in Chile and was the CEO for Cable and Wireless Caribbean and Altice in the Dominican Republic (integrating Orange with Tricom), in addition to senior leadership positions with Ericsson. During his tenure at Cable and Wireless, Martin also served on the Board of Directors of TSTT in Trinidad and Tobago. Martin holds an MSc in Economics from Stockholm School of Economics, a MSc in Chemical Engineering from The Royal Institute of Technology in Stockholm. Sten Dahlborg: Sten Dahlborg is an accomplished executive with over 20 years of experience in the Medtech industry and investment management. He has served as the chairman and managing director of several companies, including Ascilion and CGI Healthcare, where he successfully led strategic exits and business development initiatives. As a business advisor and board member for various medical technology firms, he has played a pivotal role in fostering innovation and commercialization within the sector. Currently, Sten is the CEO of CGI Ventures AB, advising new businesses on strategic growth and mergers and acquisitions, and serves as a co-owner of CITRUS MÉXICO. His expertise in adaptive leadership and investment management, coupled with a strong focus on commercial success, positions him as a leader in driving advancements in healthcare technology.お知らせ • Oct 11PMD Device Solutions Announces Board and Executive ChangesPMD Device Solutions announced that its largest founding shareholder, Miman Ventures AB, has requested the Board of PMDS to convene an Extraordinary General Meeting (EGM) to appoint new Non-Executive Directors. This request follows recent management changes and forms part of a broader transition in the company's governance and operational structure. The company has recently seen the resignation of Magnus Christensen, Christer Ahlberg, and Anne Dorney. Anne, who has been an Executive Director, will also be retiring with immediate effect from her role as Chief Compliance Officer. In light of these departures, PMDS will actively engage in appointing new individuals who will support the company's continued growth.Reported Earnings • Aug 23Second quarter 2024 earnings releasedSecond quarter 2024 results: Revenue: kr12.4m (up 2.6% from 2Q 2023). Net loss: kr11.7m (loss widened 85% from 2Q 2023). Revenue is forecast to grow 50% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Biotechs industry in Europe.お知らせ • Jun 26PMD Device Solutions AB Revises Earnings Guidance for the Year 2026PMD Device Solutions AB revised earnings guidance for the year 2026. The company revised its annual recurring revenue (ARR) target from SEK 100 million to SEK 260 million by yearend 2026. The increase is driven by the current strong business activity in the UK and the acquisition and subsequent restructuring of the US remote patient monitoring company. PMDS initially forecasted SEK 100 million of annual recurring revenue as part of its listing in January 2024.New Risk • Jun 10New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -kr18m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr18m free cash flow). Share price has been highly volatile over the past 3 months (15% average weekly change). Negative equity (-kr106m). Minor Risks Less than 3 years of financial data is available. Revenue is less than US$5m (kr37m revenue, or US$3.5m). Market cap is less than US$100m (€12.9m market cap, or US$13.9m).最新情報をもっと見るRecent updatesNew Risk • Nov 07New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Negative equity (-kr115m). Market cap is less than US$10m (€5.17m market cap, or US$5.55m). Minor Risks Less than 3 years of financial data is available. Revenue is less than US$5m (kr40m revenue, or US$3.7m).お知らせ • Oct 29PMD Device Solutions AB Approves Board ChangesPMD Device Solutions AB at its EGM held on October 29, 2024 approved that the board of directors shall consist of Martin Roos (new election) and Sten Dahlborg (new election). It was further resolved to elect Sten Dahlborg as chairman of the board. Peter Donnelly therefore resigns as member of the board as well as chairman. Martin Roos: Martin Roos is an INSEAD certified board director (IDP) with board and executive experience from telecom, tech and biotech. He currently serves as the chairman for Seamless Distribution Systems and is a board member of Nexam Chemicals and Redsense Medical (listed on NGM Nordic SME, Nasdaq First North and Spotlight respectively). He also serves on the board of startups such as Lignin Industries. Martin has previously served on the board operating committee of WOM in Chile and was the CEO for Cable and Wireless Caribbean and Altice in the Dominican Republic (integrating Orange with Tricom), in addition to senior leadership positions with Ericsson. During his tenure at Cable and Wireless, Martin also served on the Board of Directors of TSTT in Trinidad and Tobago. Martin holds an MSc in Economics from Stockholm School of Economics, a MSc in Chemical Engineering from The Royal Institute of Technology in Stockholm. Sten Dahlborg: Sten Dahlborg is an accomplished executive with over 20 years of experience in the Medtech industry and investment management. He has served as the chairman and managing director of several companies, including Ascilion and CGI Healthcare, where he successfully led strategic exits and business development initiatives. As a business advisor and board member for various medical technology firms, he has played a pivotal role in fostering innovation and commercialization within the sector. Currently, Sten is the CEO of CGI Ventures AB, advising new businesses on strategic growth and mergers and acquisitions, and serves as a co-owner of CITRUS MÉXICO. His expertise in adaptive leadership and investment management, coupled with a strong focus on commercial success, positions him as a leader in driving advancements in healthcare technology.お知らせ • Oct 11PMD Device Solutions Announces Board and Executive ChangesPMD Device Solutions announced that its largest founding shareholder, Miman Ventures AB, has requested the Board of PMDS to convene an Extraordinary General Meeting (EGM) to appoint new Non-Executive Directors. This request follows recent management changes and forms part of a broader transition in the company's governance and operational structure. The company has recently seen the resignation of Magnus Christensen, Christer Ahlberg, and Anne Dorney. Anne, who has been an Executive Director, will also be retiring with immediate effect from her role as Chief Compliance Officer. In light of these departures, PMDS will actively engage in appointing new individuals who will support the company's continued growth.Reported Earnings • Aug 23Second quarter 2024 earnings releasedSecond quarter 2024 results: Revenue: kr12.4m (up 2.6% from 2Q 2023). Net loss: kr11.7m (loss widened 85% from 2Q 2023). Revenue is forecast to grow 50% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Biotechs industry in Europe.お知らせ • Jun 26PMD Device Solutions AB Revises Earnings Guidance for the Year 2026PMD Device Solutions AB revised earnings guidance for the year 2026. The company revised its annual recurring revenue (ARR) target from SEK 100 million to SEK 260 million by yearend 2026. The increase is driven by the current strong business activity in the UK and the acquisition and subsequent restructuring of the US remote patient monitoring company. PMDS initially forecasted SEK 100 million of annual recurring revenue as part of its listing in January 2024.New Risk • Jun 10New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -kr18m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr18m free cash flow). Share price has been highly volatile over the past 3 months (15% average weekly change). Negative equity (-kr106m). Minor Risks Less than 3 years of financial data is available. Revenue is less than US$5m (kr37m revenue, or US$3.5m). Market cap is less than US$100m (€12.9m market cap, or US$13.9m).お知らせ • Apr 09PMD Device Solutions AB (OM:PMDS) intends to acquire Coala Life Inc. from Coala-Life Group AB (publ).PMD Device Solutions AB (OM:PMDS) intends to acquire Coala Life Inc. from Coala-Life Group AB (publ) on April 9, 2024. On March 22, 2024, the Board of Directors of Coala Life filed for bankruptcy. The transaction will be closed no later than April 10th, 2024.お知らせ • Mar 01+ 4 more updatesPMD Device Solutions AB to Report Nine Months, 2024 Results on Nov 22, 2024PMD Device Solutions AB announced that they will report nine months, 2024 results on Nov 22, 2024お知らせ • Jan 24PMD Device Solutions AB to Report Fiscal Year 2023 Results on Feb 29, 2024PMD Device Solutions AB announced that they will report fiscal year 2023 results on Feb 29, 2024株主還元8T00DE BiotechsDE 市場7D0%-1.0%0.6%1Y-97.5%-11.9%0.2%株主還元を見る業界別リターン: 8T00過去 1 年間で-11.9 % の収益を上げたGerman Biotechs業界を下回りました。リターン対市場: 8T00は、過去 1 年間で0.2 % のリターンを上げたGerman市場を下回りました。価格変動Is 8T00's price volatile compared to industry and market?8T00 volatility8T00 Average Weekly Movement35.5%Biotechs Industry Average Movement8.8%Market Average Movement6.1%10% most volatile stocks in DE Market13.2%10% least volatile stocks in DE Market2.7%安定した株価: 8T00の株価は、 German市場と比較して過去 3 か月間で変動しています。時間の経過による変動: 8T00の 週次ボラティリティ は、過去 1 年間で29%から36%に増加しました。会社概要設立従業員CEO（最高経営責任者ウェブサイト201129Myles Murraywww.pmd-solutions.comPMD Device Solutions AB社はデジタル医療機器メーカーで、アイルランドで呼吸モニタリング・ソリューションを開発・販売している。同社は、患者の悪化を早期に発見し、予防可能な呼吸不全や有害な患者の転帰を回避するために呼吸数をモニタリングするソリューション、レスピラセンス、あらゆる病棟の遠隔モニタリングを可能にするレスピラセンス・エア、レスピラセンス・エアの遠隔測定システムを使用し、ハイリスク患者用の追加ワイヤレス周辺センサーを接続するEWSを提供している。また、24時間365日のビデオサポート、技術管理、レポーティング、デジタル包括性、二次モニタリング、患者の入院から退院までのエンドツーエンド管理などのバーチャル病棟サービスも提供している。PMD Device Solutions ABは2011年に設立され、アイルランドのコークに本社を置いている。もっと見るPMD Device Solutions AB 基礎のまとめPMD Device Solutions の収益と売上を時価総額と比較するとどうか。8T00 基礎統計学時価総額€1.49m収益（TTM）-€4.15m売上高(TTM)€3.40m0.4xP/Sレシオ-0.4xPER（株価収益率8T00 は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計8T00 損益計算書（TTM）収益SEK 39.12m売上原価SEK 8.68m売上総利益SEK 30.43mその他の費用SEK 78.09m収益-SEK 47.65m直近の収益報告Sep 30, 2024次回決算日Feb 26, 2025一株当たり利益（EPS）-1.84グロス・マージン77.80%純利益率-121.82%有利子負債／自己資本比率-23.9%8T00 の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2025/01/16 19:14終値2024/12/23 00:00収益2024/09/30年間収益2023/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋PMD Device Solutions AB 1 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1 アナリスト機関Johan UnnerusRedeye
New Risk • Nov 07New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Negative equity (-kr115m). Market cap is less than US$10m (€5.17m market cap, or US$5.55m). Minor Risks Less than 3 years of financial data is available. Revenue is less than US$5m (kr40m revenue, or US$3.7m).
お知らせ • Oct 29PMD Device Solutions AB Approves Board ChangesPMD Device Solutions AB at its EGM held on October 29, 2024 approved that the board of directors shall consist of Martin Roos (new election) and Sten Dahlborg (new election). It was further resolved to elect Sten Dahlborg as chairman of the board. Peter Donnelly therefore resigns as member of the board as well as chairman. Martin Roos: Martin Roos is an INSEAD certified board director (IDP) with board and executive experience from telecom, tech and biotech. He currently serves as the chairman for Seamless Distribution Systems and is a board member of Nexam Chemicals and Redsense Medical (listed on NGM Nordic SME, Nasdaq First North and Spotlight respectively). He also serves on the board of startups such as Lignin Industries. Martin has previously served on the board operating committee of WOM in Chile and was the CEO for Cable and Wireless Caribbean and Altice in the Dominican Republic (integrating Orange with Tricom), in addition to senior leadership positions with Ericsson. During his tenure at Cable and Wireless, Martin also served on the Board of Directors of TSTT in Trinidad and Tobago. Martin holds an MSc in Economics from Stockholm School of Economics, a MSc in Chemical Engineering from The Royal Institute of Technology in Stockholm. Sten Dahlborg: Sten Dahlborg is an accomplished executive with over 20 years of experience in the Medtech industry and investment management. He has served as the chairman and managing director of several companies, including Ascilion and CGI Healthcare, where he successfully led strategic exits and business development initiatives. As a business advisor and board member for various medical technology firms, he has played a pivotal role in fostering innovation and commercialization within the sector. Currently, Sten is the CEO of CGI Ventures AB, advising new businesses on strategic growth and mergers and acquisitions, and serves as a co-owner of CITRUS MÉXICO. His expertise in adaptive leadership and investment management, coupled with a strong focus on commercial success, positions him as a leader in driving advancements in healthcare technology.
お知らせ • Oct 11PMD Device Solutions Announces Board and Executive ChangesPMD Device Solutions announced that its largest founding shareholder, Miman Ventures AB, has requested the Board of PMDS to convene an Extraordinary General Meeting (EGM) to appoint new Non-Executive Directors. This request follows recent management changes and forms part of a broader transition in the company's governance and operational structure. The company has recently seen the resignation of Magnus Christensen, Christer Ahlberg, and Anne Dorney. Anne, who has been an Executive Director, will also be retiring with immediate effect from her role as Chief Compliance Officer. In light of these departures, PMDS will actively engage in appointing new individuals who will support the company's continued growth.
Reported Earnings • Aug 23Second quarter 2024 earnings releasedSecond quarter 2024 results: Revenue: kr12.4m (up 2.6% from 2Q 2023). Net loss: kr11.7m (loss widened 85% from 2Q 2023). Revenue is forecast to grow 50% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Biotechs industry in Europe.
お知らせ • Jun 26PMD Device Solutions AB Revises Earnings Guidance for the Year 2026PMD Device Solutions AB revised earnings guidance for the year 2026. The company revised its annual recurring revenue (ARR) target from SEK 100 million to SEK 260 million by yearend 2026. The increase is driven by the current strong business activity in the UK and the acquisition and subsequent restructuring of the US remote patient monitoring company. PMDS initially forecasted SEK 100 million of annual recurring revenue as part of its listing in January 2024.
New Risk • Jun 10New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -kr18m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr18m free cash flow). Share price has been highly volatile over the past 3 months (15% average weekly change). Negative equity (-kr106m). Minor Risks Less than 3 years of financial data is available. Revenue is less than US$5m (kr37m revenue, or US$3.5m). Market cap is less than US$100m (€12.9m market cap, or US$13.9m).
New Risk • Nov 07New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Negative equity (-kr115m). Market cap is less than US$10m (€5.17m market cap, or US$5.55m). Minor Risks Less than 3 years of financial data is available. Revenue is less than US$5m (kr40m revenue, or US$3.7m).
お知らせ • Oct 29PMD Device Solutions AB Approves Board ChangesPMD Device Solutions AB at its EGM held on October 29, 2024 approved that the board of directors shall consist of Martin Roos (new election) and Sten Dahlborg (new election). It was further resolved to elect Sten Dahlborg as chairman of the board. Peter Donnelly therefore resigns as member of the board as well as chairman. Martin Roos: Martin Roos is an INSEAD certified board director (IDP) with board and executive experience from telecom, tech and biotech. He currently serves as the chairman for Seamless Distribution Systems and is a board member of Nexam Chemicals and Redsense Medical (listed on NGM Nordic SME, Nasdaq First North and Spotlight respectively). He also serves on the board of startups such as Lignin Industries. Martin has previously served on the board operating committee of WOM in Chile and was the CEO for Cable and Wireless Caribbean and Altice in the Dominican Republic (integrating Orange with Tricom), in addition to senior leadership positions with Ericsson. During his tenure at Cable and Wireless, Martin also served on the Board of Directors of TSTT in Trinidad and Tobago. Martin holds an MSc in Economics from Stockholm School of Economics, a MSc in Chemical Engineering from The Royal Institute of Technology in Stockholm. Sten Dahlborg: Sten Dahlborg is an accomplished executive with over 20 years of experience in the Medtech industry and investment management. He has served as the chairman and managing director of several companies, including Ascilion and CGI Healthcare, where he successfully led strategic exits and business development initiatives. As a business advisor and board member for various medical technology firms, he has played a pivotal role in fostering innovation and commercialization within the sector. Currently, Sten is the CEO of CGI Ventures AB, advising new businesses on strategic growth and mergers and acquisitions, and serves as a co-owner of CITRUS MÉXICO. His expertise in adaptive leadership and investment management, coupled with a strong focus on commercial success, positions him as a leader in driving advancements in healthcare technology.
お知らせ • Oct 11PMD Device Solutions Announces Board and Executive ChangesPMD Device Solutions announced that its largest founding shareholder, Miman Ventures AB, has requested the Board of PMDS to convene an Extraordinary General Meeting (EGM) to appoint new Non-Executive Directors. This request follows recent management changes and forms part of a broader transition in the company's governance and operational structure. The company has recently seen the resignation of Magnus Christensen, Christer Ahlberg, and Anne Dorney. Anne, who has been an Executive Director, will also be retiring with immediate effect from her role as Chief Compliance Officer. In light of these departures, PMDS will actively engage in appointing new individuals who will support the company's continued growth.
Reported Earnings • Aug 23Second quarter 2024 earnings releasedSecond quarter 2024 results: Revenue: kr12.4m (up 2.6% from 2Q 2023). Net loss: kr11.7m (loss widened 85% from 2Q 2023). Revenue is forecast to grow 50% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Biotechs industry in Europe.
お知らせ • Jun 26PMD Device Solutions AB Revises Earnings Guidance for the Year 2026PMD Device Solutions AB revised earnings guidance for the year 2026. The company revised its annual recurring revenue (ARR) target from SEK 100 million to SEK 260 million by yearend 2026. The increase is driven by the current strong business activity in the UK and the acquisition and subsequent restructuring of the US remote patient monitoring company. PMDS initially forecasted SEK 100 million of annual recurring revenue as part of its listing in January 2024.
New Risk • Jun 10New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -kr18m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr18m free cash flow). Share price has been highly volatile over the past 3 months (15% average weekly change). Negative equity (-kr106m). Minor Risks Less than 3 years of financial data is available. Revenue is less than US$5m (kr37m revenue, or US$3.5m). Market cap is less than US$100m (€12.9m market cap, or US$13.9m).
お知らせ • Apr 09PMD Device Solutions AB (OM:PMDS) intends to acquire Coala Life Inc. from Coala-Life Group AB (publ).PMD Device Solutions AB (OM:PMDS) intends to acquire Coala Life Inc. from Coala-Life Group AB (publ) on April 9, 2024. On March 22, 2024, the Board of Directors of Coala Life filed for bankruptcy. The transaction will be closed no later than April 10th, 2024.
お知らせ • Mar 01+ 4 more updatesPMD Device Solutions AB to Report Nine Months, 2024 Results on Nov 22, 2024PMD Device Solutions AB announced that they will report nine months, 2024 results on Nov 22, 2024
お知らせ • Jan 24PMD Device Solutions AB to Report Fiscal Year 2023 Results on Feb 29, 2024PMD Device Solutions AB announced that they will report fiscal year 2023 results on Feb 29, 2024
